Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more
Hansa Biopharma AB (publ) (HNSBF) - Total Liabilities
Latest total liabilities as of December 2025: $1.25 Billion USD
Based on the latest financial reports, Hansa Biopharma AB (publ) (HNSBF) has total liabilities worth $1.25 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hansa Biopharma AB (publ) - Total Liabilities Trend (2008–2025)
This chart illustrates how Hansa Biopharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hansa Biopharma AB (publ) Competitors by Total Liabilities
The table below lists competitors of Hansa Biopharma AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangyin Pivot Automotive Products Co. Ltd.
SHE:301181
|
China | CN¥200.94 Million |
|
Ability Opto-Electronics Technology Co Ltd
TWO:3362
|
Taiwan | NT$6.66 Billion |
|
Lutian Machinery Co Ltd
SHG:605259
|
China | CN¥702.28 Million |
|
dotdigital Group Plc
PINK:DOTDF
|
USA | $33.53 Million |
|
Nextool Technology Co. Ltd. A
SHG:688419
|
China | CN¥216.86 Million |
|
Bestore Co Ltd
SHG:603719
|
China | CN¥1.69 Billion |
|
Zhejiang Golden Eagle Co Ltd
SHG:600232
|
China | CN¥918.40 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Hansa Biopharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -14.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hansa Biopharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hansa Biopharma AB (publ) (2008–2025)
The table below shows the annual total liabilities of Hansa Biopharma AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.25 Billion | -10.04% |
| 2024-12-31 | $1.39 Billion | +17.25% |
| 2023-12-31 | $1.19 Billion | +9.35% |
| 2022-12-31 | $1.08 Billion | +324.90% |
| 2021-12-31 | $255.24 Million | +32.68% |
| 2020-12-31 | $192.37 Million | +89.68% |
| 2019-12-31 | $101.42 Million | +19.40% |
| 2018-12-31 | $84.94 Million | +70.73% |
| 2017-12-31 | $49.75 Million | +84.42% |
| 2016-12-31 | $26.98 Million | +114.77% |
| 2015-12-31 | $12.56 Million | +178.72% |
| 2014-12-31 | $4.51 Million | -11.57% |
| 2013-12-31 | $5.10 Million | +99.38% |
| 2012-12-31 | $2.56 Million | -58.70% |
| 2011-12-31 | $6.19 Million | +9.82% |
| 2010-12-31 | $5.64 Million | -57.39% |
| 2009-12-31 | $13.23 Million | +220.05% |
| 2008-12-31 | $4.13 Million | -- |